Akiva Mintz, MD, PhD
Division of Nuclear Medicine
Akiva Mintz, M.D., Ph.D, is a physician-scientist whose translational research focuses on developing and personalizing cancer therapies using non-invasive molecular imaging. He obtained his medical and graduate degrees at the Pennsylvania State University College of Medicine where he helped discover and therapeutically exploit a new cancer restricted biomarker in malignant brain cancer. Dr. Mintz subsequently completed a Nuclear Medicine residency and an NIH-sponsored molecular imaging fellowship at the University of Pennsylvania, where he developed novel preclinical multimodality imaging tools to non-invasively visualize disease and early response to therapy. Dr. Mintz is Dual-Board Certified in Nuclear Medicine and Clinical Informatics. In addition to his medical training, Dr. Mintz is a CFA charterholder and completed a Masters in Healthcare Administration (MHA) at the University of North Carolina at Chapel Hill.
Dr. Mintz is Professor of Radiology at Columbia University Medical Center and Attending Radiologist at New York Presbyterian Hospital. He also is Vice Chairman of Translational Research, Director of the Kreitchman PET Center and Division Chief of the Nuclear Medicine division. Prior to Columbia, Dr. Mintz worked at Wake Forest, where he held a number of leadership roles, including Vice Chair of Radiology and Section Head of Nuclear Medicine. Dr. Mintz was also the Associated Director of the Wake Forest Clinical and Translational Science Institute and Co-leader of the Cancer Biology and Biochemistry Program of the NCI-designated Wake Forest Comprehensive Cancer Center.
Dr. Mintz’s cross-translational research efforts exploit nuclear-based molecular imaging and therapy techniques to personalize anti-cancer therapies. His work is funded by multiple NIH grants and the American Cancer Society.
1. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya D, Almaguel F, Wadas T, Herpai D, Debinski W, *Mintz A. IL13RA2 targeted alpha particle therapy against glioblastoma. In Press, Oncotarget (2017).
2. Prabhakaran J, Zanderigo F, Solingapuram Sai KK, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Mintz A, Mann JJ, Kumar D. Radiosynthesis and In Vivo Evaluation of [11C]A1070722, a High Affinity GSK3 PET Tracer in Primate Brain. In Press, ACS Chemical Neuroscience (2017).
3. Prazeres P, Sena I, Borges I, Azevedo P, Andreotti J, Paiva A, Almeida V, Guerra DA, Santos G, Mintz A, Delbono O, Birbrair A. Pericytes are heterogeneous in their origin within the same tissue (2017) in press Developmental Biology.
4. Solingapuram Sai KK, Prabhakaran J, Sattiraju A, Mann JJ, Mintz A, Kumar JSD. Radiosynthesis and evaluation of IGF1R PET ligand [11C]GSK1838705A. In Press Bioorganic & Medicinal Chemistry Letters (2017).
5. Sun Y, Xiong X, Pandya D, Jung Y, Mintz A*(corresponding), Hayasaka S, Wadas TJ, Li KC. Enhancing tissue permeability with MRI guided preclinical focused ultrasound system in rabbit muscle: from normal tissue to VX2 tumor. In Press Journal of Controlled Release (2017).
6. Tyrrell DJ, Bharadwaj MS , Jorgensen, MJ, Register TC, Shively C, Andrews R, Neth B, Keene CD, Mintz A, Craft S, Molina AJA. Blood-Based Bioenergetic Profiling Reflects Differences in Brain Bioenergetics and Metabolism. Oxidative Medicine and Cellular Longevity. In Press (2017).
7. Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E, Gupta N, Knopman DS, Mintz A, Rahmim A, Sharrett AR, Wagenknecht LE, Wong DF, Mosley TH. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA (2017) 317 (14), 1443-1450.
8. Solingapuram Sai KK, Sattiraju A, Almaguel FG, Xuan A, Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, *Mintz A. Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. In Press, Oncotarget (2017).
9. Solingapuram Sai KK, Das B, Almaguel FG, Sattiraju A, *Mintz A. Radiolabeling and initial biological evaluation of [18F]KBM-1 for imaging RAR-α receptors in neuroblastoma. Bioorganic & Medicinal Chemistry Letters (2017) 27 (6), 1425-1427.
10. Solingapuram Sai KK, Mintz A. Metabolic PET Imaging. (2017) In Press, American Journal of Roentgenology (AJR).
11. Sattiraju A, Solingapuram Sai KK, Mintz A. GBM stem cells in the tumor microenvironment. Advances in Experimental Medicine and Biology (Springer). Accepted for Publication (2017).
12. Wang L, Habib AA, Mintz A, Li KC, Zhao D. Phosphatidylserine-targeted nanotheranostics for brain tumor imaging and therapeutic potential. (2017) In Press, Molecular Imaging.
13. Solingapuram Sai KK, Gage D, Neth B, Hughes, Tremblay S., Castellano CA, Cunnane S, Jorgenson M, Kaplan J, Craft S. Mintz A*. Automated Synthesis of [11C]acetoacetate on a TRASIS AIO module with non-human primate whole body PET imaging. Applied Radiation and Isotopes (2016) Accepted for publication.
14. Hu Y, Feng X, Mintz A, Petty W, Hsu W. Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. Oncotarget (2016) 7:87124.
15. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ. Kumar D. In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate Bioorganic & Medicinal Chemistry Letters (2016) 27 (1), 21-23
16. Y Hu, R Singh, Z Deng, A Mintz, W Hsu. Liposome-Protamine-DNA Nanoparticle-Mediated Delivery of Short Hairpin RNA Targeting Brachyury Inhibits Chordoma Cell Growth. Journal of Biomedical Nanotechnology (2016) 12 (10), 1952-1961.
17. Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossma SA, Schiff D, Wahl RL. Repeatability of 18F-FLT PET in a Multi-Center Study of Patients with High Grade Glioma. (2016) Journal of Nuclear Medicne and Moleclar Imaging 58:393-398.
18. Birbrair A, Sattiraju A, Zhu D, Zulato G, Batista I, Nguyen VT, Messi, ML, Solingapuram Sai KK, Marini FC, Delbono O, *Mintz A. Novel Peripherally Derived Neural-Like Stem Cells as Therapeutic Carriers for Treating Glioblastomas (2016) Stem Cells Translational Medicine 5:1-11.
19. RF Gottesman, ALC Schneider, Y Zhou, X Chen, E Green, N Gupta, DS Knopman, A Mintz, A Rahmim, AR Sharrett, LE Wagenknecht, DF Wong, TH Mosley. The ARIC-PET Amyloid Imaging Study: Brain Amyloid Differences by Age, Race, Sex, and APOE. (2016) Neurology 87 (5), 473-480.
20. Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, Mintz A, Li KC, Wadas TJ. Preliminary therapy evaluation of (225)ac-dota-c(rgdyk) demonstrates that cerenkov radiation derived from (225)ac daughter decay can be detected by optical imaging for in vivo tumor visualization. Theranostics. 2016;6:698-709.
21. Xiong X, Sun Y, Sattiraju A, Jung Y, Mintz A, Hayasaka S, Li KC. Remote spatiotemporally controlled and biologically selective permeabilization of blood-brain barrier. J Control Release. 2015; 217:113-120. PMCID: PMC4623944.
22. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes at the intersection between tissue regeneration and pathology. Clinical science. 2015;128:81-93.
23. Sai KKS, Gage D, Nader M, Mach RH, *Mintz A. Improved automated radiosynthesis of [(11)C]PBR28. Sci Pharm. 2015; 83(3):413-427. PMCID: PMC4727796.
24. Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Prah M, Schmainda K, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak D, Mankof DA. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed gbm using 18F-FMISO PET and MRI. Clinical Cancer Research 22 (20), 5079-5086.
25. Tamam M, *Mintz A. Pseudoaneurysm of a pancreas allograft artery detected by 99mtc red blood cell SPECT/CT. Clin Nucl Med. 2015;40:e241-244.
26. Wadas TJ, Pandya DN, Solingapuram Sai KK, *Mintz A. Molecular targeted alpha-particle therapy for oncologic applications. AJR Am J Roentgenol. 2014;203:253-260.
27. Hu Y, Mintz A, Shah SR, Quinones-Hinojosa A, Hsu W. The fgfr/mek/erk/brachyury pathway is critical for chordoma cell growth and survival. Carcinogenesis. 2014;35:1491-1499.
28. *Mintz, A. PET/CT in Prostate Cancer: An Unmet Clinical Need. 2014. (Commentary) Oncology, 2014;28:1057-65. 2.
29. #Eriksson O, #Mintz A, Liu C, Yu M, Naji A, Alavi A. On the use of [18F]FDOPA as an imaging biomarker for transplanted islet mass. Annals of nuclear medicine. 2014;28:47-52
30. Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis. American journal of physiology. Cell physiology. 2014;307:C25-38.
31. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes: Multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Frontiers in aging neuroscience. 2014;6:245.
32. Birbrair A, Zhang T, Files DC, Mannava S, Smith T, Wang ZM, Messi ML, Mintz A, Delbono O. Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. Stem cell research & therapy. 2014;5:122.
33. Kota G, Gupta P, *Mintz A. PET/CT illustration of metastatic breast cancer to the left mandibular foramen. Clin Nucl Med. 2013;38:385-386.
34. Kota G, Gupta P, Lesser GJ, Wilson JA, Mintz A. Somatostatin receptor molecular imaging for metastatic intracranial hemangiopericytoma. Clin Nucl Med. 2013;38:984-987.
35. Deford-Watts LM, Mintz A, Kridel SJ. The potential of (1)(1)c-acetate PET for monitoring the fatty acid synthesis pathway in tumors. Current pharmaceutical biotechnology. 2013;14:300-312.
36. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Type-1 pericytes participate in fibrous tissue deposition in aged skeletal muscle. American journal of physiology. Cell physiology. 2013;305:C1098-1113.
37. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN, Mintz A, Delbono O. Skeletal muscle neural progenitor cells exhibit properties of ng2-glia. Exp Cell Res. 2013;319:45-63.
38. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN, Mintz A, Delbono O. Skeletal muscle pericyte subtypes differ in their differentiation potential. Stem Cell Res. 2013;10:67-84.
39. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN, Mintz A, Delbono O. Role of pericytes in skeletal muscle regeneration and fat accumulation. Stem Cells Dev. 2013;22:2298-2314.
40. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, *Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13ralpha2 tumor-restricted biomarker. Neuro Oncol. 2012;14:1239-1253.
41. Gupta P, Kota G, *Mintz A. Evolution of a ureteric stone from the renal pelvis to the ureter on skeletal scintigraphy with ct correlation. Clin Nucl Med. 2012;37:188-189.
42. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. Ephrina1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012;32:3253-3264.
43. Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, *Mintz A. IL-13ralpha2-targeted therapy escapees: Biologic and therapeutic implications. Transl Oncol. 2011;4:390-400.
44. Gupta P, Kota G, Alavi A, *Mintz A. Unilateral diffusely increased muscle uptake of f-18 fdg in a patient with hemiparesis due to stroke. Clin Nucl Med. 2011;36:1140-1141.
45. Nguyen V, Conyers JM, *Mintz A. Pretargeting the masses: A means of improving and mainstreaming targeted molecular delivery? Cancer Biol Ther. 2010;10:775-779.
46. Kota GK, Gupta P, Conyers JM, *Mintz A. Targeting angiogenesis in an age of personalized medicine. Cancer Biol Ther. 2010;10:874-877.
47. Nguyen V, *Mintz A. New frontiers in biomarker-targeted molecular imaging. Cancer Biol Ther. 2009;8:2248-2251.
48. Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther. 2009;8:3285-3295.
49. Mintz A, Gibo DM, MadhanKumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biotherapy & Radiopharmaceuticals. 2008;23:581-589.
50. Mintz A, Wang L, Ponde DE. Comparison of radiolabeled choline and ethanolamine as probe for c